Notable Decrease of Malignant Pleural Effusion After Treatment with Sorafenib in Radioiodine-Refractory Follicular Thyroid Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Notable Decrease of Malignant Pleural Effusion After Treatment with Sorafenib in Radioiodine-Refractory Follicular Thyroid Carcinoma

Published:2014-07 Issue:7 Volume:24 Page:1179-1183
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Liu Min¹,Shen Yan²³,Ruan Maomei¹,Li Minghua²,Chen Libo¹

Affiliation:

1. Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

2. Institute of Diagnostic and Interventional Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

3. Department of Radiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2013.0703

Reference27 articles.

1. American Cancer Society 2012 Cancer Facts & Figures 2012. American Cancer Society Inc, Atlanta.

2. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma

3. Pleural Effusion in Patients With Differentiated Papillary Thyroid Cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second radioiodine treatment hardly benefits TT-DTC patients with radioiodine-negative metastases on initial post-therapeutic whole-body scans;The Quarterly Journal of Nuclear Medicine and Molecular Imaging;2023-12

2. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit;Head and Neck Tumors (HNT);2023-03-09

3. Derrame pleural maligno como presentación inicial en un cáncer tiroideo diferenciado. Reporte de un caso;Gaceta Mexicana de Oncolog�a;2022-07-11

4. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit;The Oncologist;2022-04-28

5. Novel therapies for malignant pleural effusion: Anti‑angiogenic therapy and immunotherapy (Review);International Journal of Oncology;2021-01-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3